TWI808627B - Contact lens product - Google Patents

Abstract

A contact lens product includes a contact lens and a buffer solution. The contact lens is stored in the buffer solution. The buffer solution includes at least one antioxidant. The contact lens includes at least one curcuminoid. Therefore, it is favorable for the contact lens to effectively absorb high-energy UV light or blue light of the environment and convert into weak-energy light, so that the retina can be protected and the damages thereon can be reduced effectively.

Description

contact lens products

The present invention relates to a contact lens product, and more particularly to a contact lens product that helps reduce stray light and eliminate glare.

In order to protect the eyes from strong energy light damage, general contact lenses use chemically synthesized UV/blue light absorbers to achieve the blocking effect, but because the traditional light absorbers touch the eyes, they will easily cause discomfort, and excessive doses may even cause serious eye immune reactions or poison damage. dione) cannot have a good bonding effect with the contact lens monomer, resulting in easy release from the contact lens, and even unable to overcome the high temperature and high pressure sterilization process to cause decomposition.

According to the present invention, a contact lens product is provided, which comprises a contact lens and a buffer solution. Contact lenses are stored in a buffer solution, wherein the buffer solution includes at least one antioxidant. The contact lens comprises at least one curcumin derivative, and the curcumin derivative has a structure as shown in formula (I) or formula (II): Formula (I), wherein at least one _of R and _R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylic acid-2,3-dihydroxypropyl and hydrogen, and _R and _R are not simultaneously hydrogen; or Formula (II), Wherein at least _{one of} R and _R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylic acid-2,3-dihydroxypropyl and hydrogen, R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl, and R and _R are not hydrogen at the same time _.

Therefore, the contact lens product of the present invention is designed to include novel curcumin derivatives with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivatives of the present invention have the effect of absorbing light and changing color quickly, which helps to efficiently absorb environmental high-energy ultraviolet or blue light and convert it into weak energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem of the contact lens products being sterilized by high temperature and high pressure to destroy the stability of the curcumin derivatives, and the optimal combination of antioxidant concentrations in the buffer solution can effectively stabilize and prolong the absorption effect of the curcumin derivatives of the present invention, so as to fully exert the anti-glare protection effect of the contact lenses.

Please refer to FIG. 1 , which is a schematic diagram of a contact lens product 100 according to an embodiment of the present invention. The contact lens product 100 includes a contact lens 110 and a buffer solution 120 . The contact lens 110 is stored in the buffer solution 120, and the buffer solution 120 includes at least one antioxidant (Antioxidant).

The contact lens 110 comprises at least one curcuminoid derivative (Curcuminoid), and the curcuminoid derivative has a structure as shown in formula (I) or formula (II): Formula (I), wherein at least one _of R and _R is selected from the group consisting of hydroxyethyl methacrylate (2-Hydroxyethyl methacrylate, HEMA), methacrylic acid (Methacrylic Acid, MAA), 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester (Glycerol monomethacrylate, GMA) and hydrogen (H ₎ , and R _and R are not hydrogen at the same time; or Formula (II), Wherein at least _{one of} R and _R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylic acid-2,3-dihydroxypropyl and hydrogen, R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl, and R and _R are not hydrogen at the same time _.

In the contact lens product 100 of the present invention, the concentration by weight of the curcumin derivative in the contact lens 110 is Ccu, and the concentration by weight of the antioxidant in the buffer solution 120 is Cao, which satisfies the following conditions: 0.01≤Ccu/Cao≤10.00. Alternatively, it may satisfy the following condition: 0.02 ≤ Ccu/Cao ≤ 8.00. Alternatively, it may satisfy the following condition: 0.03 ≤ Ccu/Cao ≤ 3.00. Alternatively, it may satisfy the following condition: 0.04 ≤ Ccu/Cao ≤ 1.00. Alternatively, it may satisfy the following condition: 0.05 ≤ Ccu/Cao ≤ 0.70.

Accordingly, the contact lens 110 of the contact lens product 100 of the present invention is designed to include at least one novel curcumin derivative with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivative of the present invention has the effect of absorbing light and rapidly changing color, which helps to efficiently absorb environmental high-energy ultraviolet or blue light and convert it into weak energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product 100 of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem that the contact lens product 100 is sterilized by high temperature and high pressure to destroy the stability of the curcumin derivatives, and the optimal combination of antioxidant concentrations in the buffer solution 120 can effectively stabilize and prolong the absorption effect of the curcumin derivatives of the present invention, so as to fully exert the anti-glare protection effect of the contact lens 110. Furthermore, the curcumin derivatives of the contact lens 110 of the present invention can also be mixed with colorants to achieve the desired color change, and then applied to multifocal contact lenses that can slow down and control vision, so that it can help reduce stray light and eliminate glare. Adjusting the appropriate concentration can block strong light to exert an efficient shading effect, but the present invention is not limited thereto.

In the contact lens product 100 of the present invention, at least one of _R1 and _R2 of the curcumin derivative of formula (I) can be hydroxyethyl methacrylate, and at least one of _R3 and _R4 of the curcumin derivative of formula (II) can be hydroxyethyl methacrylate. Thereby, the compatibility of the curcumin derivatives in the manufacture of the contact lens 110 can be increased, so that the monomer material can be directly bonded to the curcumin derivatives, and has good monomer bonding efficiency.

In the contact lens product 100 of the present invention, R ₅ of the curcumin derivative of formula (II) can be methacrylic acid or 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester. Thereby, better monomer bonding efficiency can be achieved, which helps to improve the bonding compatibility between curcumin derivatives and monomer materials.

In the contact lens product 100 of the present invention, the weight percent concentration of curcumin derivatives in the contact lens 110 is Ccu, which can satisfy the following conditions: 0.01% ≤ Ccu ≤ 5.00%. Thereby, the high-energy wavelength absorption effect of the contact lens 110 containing curcumin derivatives of the present invention can be effectively extended. Alternatively, it may satisfy the following condition: 0.02% ≤ Ccu ≤ 4.00%. Alternatively, it may satisfy the following condition: 0.03% ≤ Ccu ≤ 3.00%. Alternatively, it may satisfy the following condition: 0.04% ≤ Ccu ≤ 2.00%. Alternatively, it may satisfy the following condition: 0.04% ≤ Ccu ≤ 1.00%.

In the contact lens product 100 of the present invention, the weight percent concentration of the antioxidant in the buffer solution 120 is Cao, which can satisfy the following conditions: 0.05% ≤ Cao ≤ 5.00%. Thereby, the high-energy wavelength absorption effect of the contact lens 110 containing curcumin derivatives of the present invention can be effectively prolonged. Alternatively, it may satisfy the following condition: 0.06% ≤ Cao ≤ 4.00%. Alternatively, it may satisfy the following condition: 0.07% ≤ Cao ≤ 3.00%. Alternatively, it may satisfy the following condition: 0.08% ≤ Cao ≤ 2.00%. Alternatively, it may satisfy the following condition: 0.09% ≤ Cao ≤ 1.50%.

In the contact lens product 100 of the present invention, the buffer solution 120 may further include at least one wetting agent (Wetting agent), the wetting agent is configured in the buffer solution 120, the weight percentage concentration of the wetting agent is Cad, and the concentration is defined as the weight percentage concentration of any wetting agent, which can meet the following conditions: 0.001% ≤ Cad ≤ 1.00%. Thereby, the moisturizing and lubricating effect of the contact lens 110 can be effectively provided. Alternatively, it may satisfy the following condition: 0.01% ≤ Cad ≤ 0.50%.

In the contact lens product 100 of the present invention, the molecular weight of the curcumin derivative is Wmc, which can satisfy the following condition: 400 ≤ Wmc ≤ 800. In this way, the absorption effect of the curcumin derivatives can be maintained and the monomer bonding efficiency can be improved through the combination of the optimal structure of the curcumin derivatives. Alternatively, it may satisfy the following condition: 410 ≤ Wmc ≤ 750. Alternatively, it may satisfy the following condition: 420 ≤ Wmc ≤ 700. Alternatively, it may satisfy the following condition: 430 ≤ Wmc ≤ 600. Alternatively, it may satisfy the following condition: 450 ≤ Wmc ≤ 500.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 280 nm to 310 nm is T2831, which can satisfy the following conditions: 50% ≤ T2831 ≤ 90%. Thus, properly adjusting the usage amount of the curcumin derivative can effectively improve the absorption effect of the contact lens 110 in the UVB range. Alternatively, it may satisfy the following condition: 60% ≤ T2831 ≤ 88%. Alternatively, it may satisfy the following condition: 70% ≤ T2831 ≤ 86%. Alternatively, it may satisfy the following condition: 72% ≤ T2831 ≤ 80%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 310 nm to 380 nm is T3138, which can satisfy the following conditions: 60% ≤ T3138 ≤ 92%. Thus, properly adjusting the usage amount of the curcumin derivative can effectively improve the absorption effect of the contact lens 110 in the UVA range. Alternatively, it may satisfy the following condition: 60% ≤ T3138 ≤ 85%. Alternatively, it may satisfy the following condition: 75% ≤ T3138 ≤ 85%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 410 nm to 460 nm is T4146, which can satisfy the following conditions: 70% ≤ T4146 ≤ 90%. Thus, properly adjusting the usage amount of the curcumin derivative can effectively improve the absorption effect of the contact lens 110 in the blue light range. Alternatively, it may satisfy the following condition: 75% ≤ T4146 ≤ 85%. Alternatively, it may satisfy the following condition: 80% ≤ T4146 ≤ 90%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 460 nm to 780 nm is T4678, which can satisfy the following conditions: 90% ≤ T4678 ≤ 98%. In this way, the high light transmission effect of the contact lens 110 can be effectively maintained by properly adjusting the usage amount of the curcumin derivative.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 380 nm to 780 nm is T3878, which can satisfy the following conditions: 85% ≤ T3878 ≤ 98%. In this way, by properly adjusting the amount of curcumin derivatives used, the absorption and high light transmission effects of the curcumin derivatives of the contact lens 110 can be effectively balanced.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption and barrier efficiency of the contact lens 110 at a wavelength of 280 nm to 310 nm is BE2831, which can satisfy the following conditions: 4.0% ≤ BE2831 ≤ 50.0%. In this way, the absorption effect of the high-energy UVB light of the contact lens 110 can be effectively maintained. Alternatively, it may satisfy the following condition: 5.0% ≤ BE2831 ≤ 50.0%. Alternatively, it may satisfy the following condition: 5.0% ≤ BE2831 ≤ 40.0%. Alternatively, it may satisfy the following condition: 6.0% ≤ BE2831 ≤ 30.0%. Alternatively, it may satisfy the following condition: 7.5% ≤ BE2831 ≤ 20.0%. Alternatively, it may satisfy the following condition: 10.0% ≤ BE2831 ≤ 50.0%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption and barrier efficiency of the contact lens 110 at a wavelength of 310 nm to 380 nm is BE3138, which can satisfy the following conditions: 3.0% ≤ BE3138 ≤ 35.0%. In this way, the absorption effect of the high-energy UVA light of the contact lens 110 can be effectively maintained. Alternatively, it may satisfy the following condition: 3.5% ≤ BE3138 ≤ 30.0%. Alternatively, it may satisfy the following condition: 5.0% ≤ BE3138 ≤ 35.0%. Alternatively, it may satisfy the following condition: 7.5% ≤ BE3138 ≤ 35.0%. Alternatively, it may satisfy the following condition: 10.0% ≤ BE3138 ≤ 20.0%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption and barrier efficiency of the contact lens 110 at a wavelength of 410 nm to 460 nm is BE4146, which can satisfy the following conditions: 1.0% ≤ BE4146 ≤ 30.0%. In this way, the absorption effect of the high-energy blue light of the contact lens 110 can be effectively maintained. Alternatively, it may satisfy the following condition: 1.5% ≤ BE4146 ≤ 27.0%. Alternatively, it may satisfy the following condition: 2.0% ≤ BE4146 ≤ 25.0%. Alternatively, it may satisfy the following condition: 2.5% ≤ BE4146 ≤ 23.0%. Alternatively, it may satisfy the following condition: 5.0% ≤ BE4146 ≤ 20.0%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption and barrier efficiency of the contact lens 110 at a wavelength of 460 nm to 780 nm is BE4678, which can satisfy the following conditions: 0.5% ≤ BE4678 ≤ 5.0%. Thereby, the high light transmission effect of the contact lens 110 can be effectively maintained.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption and barrier efficiency of the contact lens 110 at a wavelength of 380 nm to 780 nm is BE3878, which can satisfy the following conditions: 1.0% ≤ BE3878 ≤ 10.0%. Thereby, the absorption and high light transmission effect of the curcumin derivative of the contact lens 110 can be effectively balanced.

In the contact lens product 100 of the present invention, the contact lens 110 can comprise at least a dicurcumin derivative. In this way, curcumin derivatives can be adjusted and selected according to the desired color changing effect, and different color changing performances can be achieved by mixing multiple curcumin derivatives.

In the contact lens product 100 of the present invention, the contact lens 110 may further include at least one colorant. In this way, the discoloration zone of the contact lens 110 of the present invention can contain mixed coloring materials of curcumin derivatives, so that the discoloration zone can achieve different color changes as required. If the discoloration zone is designed to be ring-shaped smaller than the optical zone, it will help to reduce stray light, so that it has the effect of eliminating glare when applied to multifocal contact lenses with slowing down and vision control. Alternatively, if the discoloration area is designed to be disc-shaped and cover the optical area, it can block strong light to exert a dimming effect like sunglasses. Alternatively, if the discoloration area is further designed in the outer area of the non-optical area, then the appearance of the contact lens 110 can be adjusted to achieve the effect of iris enlargement.

Furthermore, in the contact lens product 100 of the present invention, the colorant of the contact lens 110 can form a pattern. Patterns can contain text, numbers or patterns, and can have directional and representative functions, and can produce identification marks, expiration date indications, direction identification, and indications of possible environmental hazards.

In the contact lens product 100 of the present invention, the contact lens 110 can comprise at least three lens layers. In this way, the leakage of the coloring material in the contact lens 110 can be avoided, and the chance of contacting the chemical substance with the eyes can be reduced.

In the contact lens product 100 of the present invention, the contact lens product 100 is a one-day disposable product, and the contact lens product 100 may further include a light-shielding package. In detail, curcumin derivatives may lose their luminous effect over time after being exposed to light, so they should be used within the expiry date when the curcumin derivatives have the maximum activity to maintain the best light-shielding or light-reducing effect, and completely light-proof packaging can block light, which can protect and maintain the curcumin derivatives in the contact lens 110, which helps long-term storage and maintains the best light-shielding or light-reducing effect.

The contact lens product 100 of the present invention is produced by the following steps: (1) Synthesize unmodified curcumin through specific synthesis steps to produce modified curcumin. (2) Add the modified curcumin to the specific formula monomer and mix evenly. (3) After the monomer mixture is homogenized, it is cured with UV/heat to produce the contact lens 110 . (4) The finished contact lens 110 will be treated with a hydration step and stored in a buffer solution 120 . (5) Sterilize the sealed package containing the contact lens 110 and the buffer solution 120 at 121°C for at least 20 minutes to obtain the contact lens product 100 of the present invention.

In the contact lens product 100 of the present invention, the steps of measuring the transmittance of the contact lens 110 in a specific wavelength range are as follows: (1) Equilibrate the contact lens 110 in a standard solution. (2) Place the contact lens 110 together with the standard solution in a quartz plate, and measure the transmittance of the contact lens 110 with an instrument under the conditions of a scanning accuracy of 1 nm and a scanning range of 200 nm to 800 nm.

All the technical features of the above-mentioned contact lens product of the present invention can be combined and configured to achieve corresponding effects.

The functions of the contact lens in the present invention can be Myopia correction, Hyperopia correction, Presbyopia correction, Astigmatism correction, Myopia control delay, Corneal reshaping, etc.

The diopter of the contact lens in the present invention is represented by D value, for example, the central diopter of the lens for correcting myopia is a negative value, and the central diopter of a lens for correcting hyperopia is a positive value. The aggravation of myopia in the present invention refers to the deepening of myopia, and the greater the absolute value of the negative diopter, for example, -0.5 D aggravates/deepens to -2.0 D.

The surface shape of the contact lens described in the present invention changes, such as spherical (Spheric), plane (Plane) or aspheric (Aspheric), and the shape of the curved surface viewed through the center shall prevail. The front surface (Front surface) of the contact lens in the present invention refers to the surface away from the cornea of the eyeball, and the back surface (Back surface) refers to the surface close to the cornea of the eyeball.

The stable structure of the contact lens in the present invention can have a rotationally stable design, such as a thickened and vertically heavy design at the bottom, a balanced design with thickened sides, an asymmetric balanced design, and a stable design with thinned top and bottom.

The structural composition of the contact lens described in the present invention can be at least two layers of lenses; wherein the colored contact lens can be composed of two layers, such as a lens body layer and a color layer; the color contact lens can be composed of three layers, such as a lens body layer, a color layer and an anti-shedding protective layer; a colored contact lens can be composed of four layers, such as a lens body layer, a first color layer, a second color layer and an anti-shedding protective layer. The color contact lens can be composed of five layers, such as a lens body layer, a first color layer, a second color layer, a third color layer and an anti-shedding protective layer. The colored contact lens can be composed of another five layers, such as a lens body layer, a first color layer, a separation layer, a second color layer and an anti-shedding protective layer.

The composition of the contact lens in the present invention includes at least two monomers, at least one crosslinking agent, at least one diluent, at least one initiator, and optionally includes an ultraviolet light absorber or a blue light absorber. In this way, the type and content of each component in the composition can be selected and adjusted, which helps to adjust the elastic coefficient of the contact lens and affect the hardness of the contact lens, thereby improving durability and stability, and can adjust the most appropriate water content of the contact lens to increase comfort and oxygen permeability. The composition includes at least four monomers, at least two cross-linking agents, at least two diluents, at least one initiator, and optionally includes an ultraviolet light absorber or a blue light absorber. In this way, a contact lens containing both the first material and the second material can be prepared.

The hydrogel monomer of the contact lens in the present invention may include: hydroxyethyl methacrylate (HEMA; 2-Hydroxyethyl methacrylate), methacrylic acid (MAA; Methacrylic Acid), 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester (GMA; Glycerol monomethacrylate), N-vinyl-2-pyrrolidinone (NVP; N-Vinyl-2-pyrrolidinone), methacrylic acid Methyl methacrylate (MMA; Methyl methacrylate), N,N-dimethylacrylamide (DMAA; N,N-Dimethyl Acrylamide), etc. In this way, it helps to maintain a moist, smooth, soft and comfortable hydration feeling, and can be worn for a long time to avoid foreign body sensation when worn.

The hydrogel of the contact lens in the present invention can be, but not limited to, the contact lens materials classified into Group 1 by the U.S. Food and Drug Administration, i.e. nonionic polymers with low water content (less than 50% by weight), such as Helfilcon A&B, Hioxifilcon B, Mafilcon, Polymacon, Tefilcon, Tetrafilcon A, etc. Alternatively, the aforementioned hydrogel can be classified as Group 2 contact lens materials by the U.S. Food and Drug Administration, that is, nonionic polymers with high water content (greater than 50 weight percent), such as Acofilcon A, Alfafilcon A, Hilafilcon B, Hioxifilcon A, Hioxifilcon B, Hioxifilcon D, Nelfilcon A, Nesofilcon A, Omafilcon A, and Samfilcon A. Alternatively, the aforementioned hydrogel can be classified as Group 3 contact lens materials by the US Food and Drug Administration, that is, ionic polymers with low water content (less than 50% by weight), such as Deltafilcon A and the like. Alternatively, the aforementioned hydrogel can be a group 4 contact lens material classified by the U.S. Food and Drug Administration, that is, an ionic polymer with a high water content (greater than 50 weight percent), such as Etafilcon A, Focofilcon A, Methafilcon A, Methafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Phemfilcon A, Vifilcon A, etc.

The silicone hydrogel monomer of the contact lens described in the present invention can be but not limited to 2-hydroxyethyl methacrylate, 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester (glycerol monomethacrylate), methacrylic acid (methacrylic acid), methacryloxypropyl three (trimethylsiloxane) silane (3-methacryloyloxypropyltris (trimethylsilyloxy ) silane), N-vinyl-2-pyrrolidinone (N-vinyl-2-pyrrolidinone), N,N-dimethylacrylamide (N,N-dimethyl acrylamide), (3-methacryloxy-2-hydroxypropoxy) propyl bis (trimethylsilyloxy) methyl (3-(3-methacryloxy-2-hydroxypropoxy) propylbis (trimethylsiloxy )methylsilane) or (3-acryloxy-2-hydroxypropoxypropyl) terminated polydimethylsiloxane). In this way, the most appropriate type of monomer can be selected, which helps to balance the parameters of the designed contact lens in terms of durability, stability, comfort, and oxygen transmission rate. It can effectively improve the oxygen transmission rate and avoid red eyes, bloodshot eyes, redness and swelling caused by corneal hypoxia, and provide long-term wearing comfort.

The silicone hydrogel of the contact lens in the present invention can be, but not limited to, the contact lens materials classified into Group 5 by the US Food and Drug Administration (USFDA), such as Balafilcon A, Comfilcon A, Efrofilcon A, Enfilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B, Narafilcon A, Narafilcon B, Senofilcon A, Delefilcon A, Somofilcon A, etc.

The product of the contact lens in the present invention can be composed of a contact lens body, a solution and a package. The contact lens body or solution can include: monomer (Monomer), UV absorber (UV Absorber), blue light absorber (Blue Absorber), beneficial agent (Beneficial agents), wetting agent (Wetting agent), pigment (Dye), myopia control agent (Myopia control agent), salts of weak acids and their conjugate bases (Acid and its conjugate base), weak base and its conjugate acid salt (Base and its conjugate acid), anionic agent (Anionic agent), cationic agent (Cationic agent) and other beneficial agents; the packaging of the present invention can be made of a combination of plastic container and aluminum foil cover, and the plastic container can be made of polypropylene (PP; Polystyrene), polystyrene (PS; Polystyrene), polyethylene terephthalate (PET; Polyethylene terephthalate) or other plastic materials can also be made of biodegradable plastics, such as PLA (Polylactic Acid), PHA (polyhydroxyalkanoates) or other degradable plastics, etc. Biodegradable plastics can also be mixed with biodegradable plasticizers (Biodegradable plasticizers) to achieve modification or modification effects; Composite aluminum foil material with plastic coating.

The initiator of the contact lens in the present invention may be but not limited to 2-hydroxy-2-methyl-1-phenyl-1-propanone (2-hydroxy-2-methyl-propiophenone). Thereby, the composition of the contact lens can effectively achieve high-efficiency polymerization reaction.

The crosslinking agent of the contact lens in the present invention may be, but not limited to, ethylene glycol dimethacrylate or trimethylol propane trimethacrylate (1,1,1-trimethylol propane trimethacrylate). Thereby, a good cross-linking effect between the monomers can be effectively obtained, and the stability and durability of the contact lens can be improved.

The diluent of contact lens described in the present invention can be polyethylene glycol 300 (polyethylene glycol 300), polyethylene glycol 600 (polyethylene glycol 600), polyethylene glycol 800 (polyethylene glycol 800), polyethylene glycol 1000 (polyethylene glycol 1000), polyethylene glycol 2000 ( polyethylene glycol 2000), polyethylene glycol 4000, 1,4-butanediol, ethanol, isopropyl alcohol, glycerol, or 1-hexanol. Thereby, the elastic coefficient of the contact lens can be assisted to be adjusted, so as to improve the wearing comfort of the contact lens.

The ultraviolet light (Ultraviolet, UV) absorber of contact lens described in the present invention can be but not limited to 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl 2-methacrylic acid (2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate), 4-methacryloxy-2-hydroxybenzophenone (4-methacryl loxy-2-hydroxybenzophenone), 2-phenylethyl acrylate, 2-phenylethyl methacrylate, 2-[2-hydroxy-5-[2-(methacryloxy)ethyl]phenyl]-2H-benzotriazole (2-(2'-hydroxy-5'-methacryloxyethyl) -2H-benzotriazole) or 2-(4-benzoyl-3-hydroxyphenoxy) ethyl acrylate (2-(4-benzoyl-3-hydroxyphenoxy) ethyl acrylate). In this way, the contact lens can absorb high-energy UV light, thereby reducing the chance of the retina being damaged by UV light.

The blue light absorbing agent of the contact lens in the present invention can be but not limited to tetraphenyl dimethacrylic acid (4-(phenyldiazenyl) phenyl methacrylate). In this way, the contact lens can absorb high-energy blue light, thereby reducing the chance of the retina being damaged by blue light.

The wetting agent of the contact lens in the present invention may include: 2-methacryloyloxyethylphosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), hyaluronic acid (Hyaluronic Acid), alginic acid (Alginic acid) or its salts and the like.

The pigment of the contact lens described in the present invention may include: Anthocyanidin, Beta-Carotene, Curcumin, Luciferin, Lutein, Lycopene, Phycobillin, Phycoerythrim, Phycocyanin, Riboflavin B2), Zeaxanthin, Photochromic dyes, Thermochromic dyes, etc., and their derivatives.

The beneficial agent of the contact lens described in the present invention may include: antibiotic (Antibotic), bacteriostatic agent (Bacteriostatic agent), antiviral agent (Antiviral agent), antifungal agent (Antifungal drugs), antiallergic agent (Antallergic agent), apomorphine (Apomorphine), bromocriptine (Bromocriptine), dopamine receptor agonist (Dopamine), Levodopa, Quinpirole, Steroid, NSAIDs, Surfactants, Miotics, Enzyme Inhibitor, Anaesthetic, Vasoconstrictor, Vitamin, Antioxidant, Nutrient, etc.

The antioxidant of the contact lens described in the present invention can be vitamin A (Vitamin A), vitamin C (Vitamin C), vitamin E (Vitamin E), uric acid (Uric acid), carotenoid (Carotenoid), flavonoid compound (Flavonoids), resveratrol (Resveratrol), methyl selenine (Selenomethionine) etc.

The myopia control agents for contact lenses in the present invention may include: cycloplegic agents, mydriatic agents (mydriatic agents), selective/non-selective muscarinic receptor antagonists, etc., which have the effect of controlling, slowing down, delaying or preventing the aggravation of myopia. For example, by blocking the M-type muscarinic receptors of the parasympathetic nerve, the ciliary muscle that paralyzes and controls the pupil can be relaxed and the pupil can be enlarged. Such as atropine (Atropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate), atropine sulfate (Atropine sulphate), cyclopentolamine ester (Cyclopentolate; 2-(Dimethylamino) ethyl (1-hydroxycyclopentyl) (phenyl) acetate), cyclopentaniline hydrochloride ( Cyclopentolate HCl), Eucatropine (Eucatropine; 1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), Homatropine (Homatropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), Nuwenxipin (Nu Venzepine), Phenylephrine HCl, Pirenzepine, Raceanisodamine, Rispenzepine, Scopolamine; (1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02, 4] non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), Scopolamine HBr, Telenzepine and Tropicamide (N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), etc., and their salts.

All the technical features of the above-mentioned contact lens product of the present invention can be combined and configured to achieve corresponding effects.

According to the above-mentioned implementation manners, specific embodiments are proposed below and described in detail with reference to the drawings.

<First to fourth examples>

In the contact lens products of the first embodiment to the fourth embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (1), and for the details of the curcumin derivatives of the first embodiment to the fourth embodiment, please refer to Table 1. Table I Curcumin Derivatives Curcumin+HEMA*1 structure Formula 1) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)C=C(OCCOC(=O)C(C)=C)\C=C\C2=CC(OC)=C(O)C=C2)=C1 molecular formula C ₂₇ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 480

In the contact lens products of the first embodiment to the fourth embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid (Hyaluronic acid, HA) and sodium alginate (Sodium Alginate, SA). For the values of Ccu, Cao, Cad, and Ccu/Cao in the first embodiment to the fourth embodiment, please refer to Table 2. Table II first embodiment 2nd embodiment 3rd embodiment 4th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

＜Example 5 to Example 8＞

In the contact lens products of the fifth embodiment to the eighth embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (2), and for the details of the curcumin derivatives of the fifth embodiment to the eighth embodiment, please refer to Table 3. Table three Curcumin Derivatives Curcumin+HEMA*1 structure Formula (2) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(OCCOC(=O)C(C)=C)C=C2)=C1 molecular formula C ₂₇ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 480

In the contact lens products of the fifth embodiment to the eighth embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the fifth embodiment to the eighth embodiment, please refer to Table 4. Table four fifth embodiment sixth embodiment Seventh embodiment Eighth embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

Please refer to Figures 2 to 6. Figure 2 shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 280 nm to 310 nm. Figure 3 shows the transmittance data of the fifth embodiment, the seventh embodiment of the present invention and the first control group at a wavelength of 310 nm to 380 nm. Figure 4 shows the fifth embodiment of the present invention, the seventh embodiment and the first control group at a wavelength of 410 nm. The transmittance data graphs from nm to 460 nm, Figure 5 shows the transmittance data graphs of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 460 nm to 780 nm, and Figure 6 shows the transmittance data graphs of the fifth embodiment, the seventh embodiment of the present invention and the first control group at wavelengths of 380 nm to 780 nm. In addition, in order to more clearly present the effect of the contact lens product of the present invention adding antioxidants to its buffer solution to overcome the effect of destroying the stability of curcumin derivatives due to high temperature and high pressure sterilization, the first control group that does not include antioxidants is further proposed here, to compare and illustrate with the fifth embodiment and the seventh embodiment, wherein the curcumin derivatives of the first control group have a structure as shown in formula (2), and Ccu=0.05%.

The values of T2831, T3138, T4146, T4678, and T3878 of the first control group, the fifth embodiment and the seventh embodiment are recorded in Table 5 on the day before the sterilization treatment (day -1), on the day of the sterilization treatment (day 0) and ten days after the sterilization treatment (day 10). Table five 1st control group fifth embodiment Seventh embodiment Antioxidants 0% Vitamin C 0.10% Vitamin C 1.00% Sterilization period (days) -1 0 10 -1 0 10 -1 0 10 T2831 93.2 87.7 92.6 90.4 87.4 86.8 93.4 16.7 75.4 T3138 93.0 94.9 95.0 90.6 90.7 91.4 93.1 76.9 81.5 T4146 92.5 96.2 97.3 90.7 94.2 95.7 92.8 90.8 89.1 T4678 99.0 99.3 99.1 98.7 98.9 98.2 98.8 99.0 97.5 T3878 97.7 98.7 98.7 97.1 97.8 97.6 97.5 97.1 95.5

In addition, based on the values of T2831, T3138, T4146, T4678, and T3878 of the first control group and the fifth embodiment and the values of T2831, T3138, T4146, T4678, and T3878 of the first control group and the seventh embodiment, the BE2831, BE3138, BE4146, BE4678, and BE3878 values of the fifth embodiment and the seventh embodiment were calculated on the day of sterilization treatment and ten days after sterilization treatment. In detail, the absorption blocking efficiency referred to in this specification is the percentage difference in average transmittance within a specific wavelength range between a contact lens product (C) containing curcumin derivatives and a general contact lens product (nC) not containing curcumin derivatives.舉例而言，以隱形眼鏡經滅菌處理後第10天於波長280 nm~310 nm的平均穿透率T2831為例計算其於波長280 nm~310 nm的吸收阻隔效率BE2831的方式如下： BE2831 = (|(C _T2831 – nC _T2831 )|/nC _T2831 )×100，其中C _T2831為包含薑黃素衍生物的隱形眼鏡產品於波長280 nm~310 nm的平均穿透率T2831的數值，而nC _T2831則為一般不含薑黃素衍生物的隱形眼鏡產品於波長280 nm~310 nm的平均穿透率T2831的數值。 The values of BE2831, BE3138, BE4146, BE4678, and BE3878 of the first control group and the fifth embodiment and the first control group and the seventh embodiment are recorded in Table 6. Table six The first control group and the fifth embodiment The first control group and the seventh embodiment Sterilization period (days) 0 10 0 10 BE2831 0.3 6.2 81.0 18.6 BE3138 4.4 3.8 19.0 14.2 BE4146 2.1 1.6 5.6 8.4 BE4678 0.4 0.9 0.4 1.7 BE3878 0.8 1.1 1.6 3.2

Please refer to Figures 7 to 11. Figure 7 shows the transmittance data graphs of the eighth embodiment of the present invention and the second control group at wavelengths of 280 nm to 310 nm. Figure 8 shows the transmittance data graphs of the eighth embodiment of the present invention and the second control group at wavelengths of 310 nm to 380 nm. Figure 9 shows the transmittance data graphs of the eighth embodiment of the invention and the second control group at wavelengths of 410 nm to 460 nm. Figure 10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 460 nm to 780 nm, and Figure 11 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 380 nm to 780 nm. In addition, in order to more clearly present the effect of the contact lens product of the present invention adding antioxidants to its buffer solution to overcome the effect of destroying the stability of curcumin derivatives due to high temperature and high pressure sterilization, the second control group that does not contain antioxidants is further proposed here to compare and illustrate with the 8th embodiment, wherein the curcumin derivatives of the second control group has a structure shown in formula (2), and Ccu=0.05%.

The values of T2831, T3138, T4146, T4678, and T3878 of the second control group and the eighth embodiment are recorded in Table 7 on the day before the sterilization treatment (day -1), the day of the sterilization treatment (the 0th day), ten days after the sterilization treatment (the 10th day) and seventeen days after the sterilization treatment (the 17th day). Table seven 2nd control group Eighth embodiment Antioxidants 0% Vitamin C 1.00% Sterilization period (days) -1 0 10 17 -1 0 10 17 T2831 87.6 84.2 85.6 88.3 87.0 22.1 72.4 51.4 T3138 84.2 90.8 91.2 92.1 83.6 73.1 76.1 60.8 T4146 77.7 95.1 96.4 96.8 76.6 77.5 80.3 74.0 T4678 98.3 99.3 99.0 98.9 98.0 97.9 97.2 94.4 T3878 94.3 98.3 98.4 98.4 93.8 93.7 93.6 89.8

In addition, based on the values of T2831, T3138, T4146, T4678, and T3878 of the second control group and the eighth embodiment, the values of BE2831, BE3138, BE4146, BE4678, and BE3878 of the eighth embodiment on the day of sterilization, ten days after sterilization, and seventeen days after sterilization were calculated. The values of BE2831, BE3138, BE4146, BE4678 and BE3878 of the second control group and the eighth embodiment are recorded in Table 8. table eight The second control group and the eighth embodiment Sterilization period (days) 0 10 17 BE2831 73.7 15.4 41.7 BE3138 19.5 16.6 33.9 BE4146 18.5 16.7 23.6 BE4678 1.4 1.9 4.6 BE3878 4.7 4.9 8.8

<9th Example to 12th Example>

In the contact lens products of the ninth embodiment to the twelfth embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (3), and for the details of the curcumin derivatives of the ninth embodiment to the twelfth embodiment, please refer to Table 9. Table nine Curcumin Derivatives Curcumin+HEMA*2 structure Formula (3) SMILES logo COC1=C(OCCOC(=O)C(C)=C)C=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(OCCOC(=O)C(C)=C)C=C2)=C1 molecular formula C ₃₃ H ₃₆ O ₁₀ Molecular weight Wmc (g/mol, Dalton) 592

In the contact lens products of the ninth embodiment to the twelfth embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the ninth embodiment to the twelfth embodiment, please refer to Table 10. table ten 9th embodiment 10th embodiment 11th embodiment 12th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Thirteenth to Sixteenth Examples>

In the contact lens products of the 13th embodiment to the 16th embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (4), and for the details of the curcumin derivatives of the 13th embodiment to the 16th embodiment, please refer to Table 11. Table Eleven Curcumin Derivatives Curcumin+HEMA*2 structure Formula (4) SMILES logo COC1=C(O)C=CC(\C=C\C(OCCOC(=O)C(C)=C)=CC(=O)\C=C\C2=CC(OC)=C(OCCOC(=O)C(C)=C)C=C2)=C1 molecular formula C ₃₃ H ₃₆ O ₁₀ Molecular weight Wmc (g/mol, Dalton) 592

In the contact lens products of the 13th to 16th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 13th to 16th embodiments, please refer to Table 12. Table 12 Thirteenth embodiment 14th embodiment 15th embodiment Sixteenth embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<The 17th embodiment to the 20th embodiment>

In the contact lens products of the 17th embodiment to the 20th embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (5), and for the details of the curcumin derivatives of the 17th embodiment to the 20th embodiment, please refer to Table 13. Table 13 Curcumin Derivatives Curcumin+HEMA*3 structure Formula (5) SMILES logo COC1=C(OCCOC(=O)C(C)=C)C=CC(\C=C\C(=O)C=C(OCCOC(=O)C(C)=C)\C=C\C2=CC(OC)=C(OCCOC(=O)C(C)=C)C=C2)=C1 molecular formula C ₃₉ H ₄₄ O ₁₂ Molecular weight Wmc (g/mol, Dalton) 704

In the contact lens products of the 17th to 20th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 17th to 20th embodiments, please refer to Table 14. Table Fourteen 17th embodiment Eighteenth embodiment Nineteenth embodiment 20th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<The twenty-first embodiment to the twenty-fourth embodiment>

In the contact lens products of the 21st embodiment to the 24th embodiment, the curcumin derivative of the contact lens has a structure shown in formula (6), and for the details of the curcumin derivatives of the 21st embodiment to the 24th embodiment, please refer to Table 15. Table 15 Curcumin Derivatives Curcumin+MAA*1 structure Formula (6) SMILES logo COC1=C(O)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OC(=O)C(C)=C)C=C2)=C1 molecular formula C ₂₅ H ₂₄ O ₇ Molecular weight Wmc (g/mol, Dalton) 436

In the contact lens products of the 21st to 24th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 21st to 24th embodiments, please refer to Table 16. Table 16 21st embodiment 22nd embodiment 23rd embodiment 24th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<The twenty-fifth to twenty-eighth examples>

In the contact lens products of the 25th embodiment to the 28th embodiment, the curcumin derivative of the contact lens has a structure shown in formula (7), and for the details of the curcumin derivatives of the 25th embodiment to the 28th embodiment, please refer to Table 17. Table 17 Curcumin Derivatives Curcumin+MAA*1 structure Formula (7) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)C=C(OC(=O)C(C)=C)\C=C\C2=CC(OC)=C(O)C=C2)=C1 molecular formula C ₂₅ H ₂₄ O ₇ Molecular weight Wmc (g/mol, Dalton) 436

In the contact lens products of the 25th to 28th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 25th to 28th embodiments, please refer to Table 18. Table 18 25th embodiment 26th embodiment 27th embodiment 28th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<The twenty-ninth embodiment to the thirty-second embodiment>

In the contact lens products of the 29th embodiment to the 32nd embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (8), and for the details of the curcumin derivatives of the 29th embodiment to the 32nd embodiment, please refer to Table 19. Table nineteen Curcumin Derivatives Curcumin+MAA*2 structure Formula (8) SMILES logo COC1=C(OC(=O)C(C)=C)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OC(=O)C(C)=C)C=C2)=C1 molecular formula C ₂₉ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 504

In the contact lens products of the 29th embodiment to the 32nd embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 29th embodiment to the 32nd embodiment, please refer to Table 20. Table twenty 29th embodiment The 30th embodiment 31st embodiment 32nd embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<The 33rd embodiment to the 36th embodiment>

In the contact lens products of the 33rd embodiment to the 36th embodiment, the curcumin derivative of the contact lens has the structure shown in formula (9), and for the details of the curcumin derivatives of the 33rd embodiment to the 36th embodiment, please refer to Table 21. Table 21 Curcumin Derivatives Curcumin+MAA*2 structure Formula (9) SMILES logo COC1=C(O)C=CC(\C=C\C(OC(=O)C(C)=C)=CC(=O)\C=C\C2=CC(OC)=C(OC(=O)C(C)=C)C=C2)=C1 molecular formula C ₂₉ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 504

In the contact lens products of the 33rd to 36th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 33rd to 36th embodiments, please refer to Table 22. Table 22 33rd embodiment 34th embodiment 35th embodiment 36th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Thirty-seventh to fortieth embodiments>

In the contact lens products of the 37th embodiment to the 40th embodiment, the curcumin derivative of the contact lens has the structure shown in formula (10), and for the details of the curcumin derivatives of the 37th embodiment to the 40th embodiment, please refer to Table 23. Table 23 Curcumin Derivatives Curcumin+MAA*3 structure Formula (10) SMILES logo COC1=C(OC(=O)C(C)=C)C=CC(\C=C\C(=O)C=C(OC(=O)C(C)=C)\C=C\C2=CC(OC)=C(OC(=O)C(C)=C)C=C2)=C1 molecular formula C ₃₃ H ₃₂ O ₉ Molecular weight Wmc (g/mol, Dalton) 572

In the contact lens products of the 37th to 40th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 37th to 40th embodiments, please refer to Table 24. Table twenty-four 37th embodiment Thirty-eighth embodiment 39th embodiment 40th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<The 41st Embodiment to the 44th Embodiment>

In the contact lens products of the 41st embodiment to the 44th embodiment, the curcumin derivative of the contact lens has a structure shown in formula (11), and for the details of the curcumin derivatives of the 41st embodiment to the 44th embodiment, please refer to Table 25. Table twenty-five Curcumin Derivatives Curcumin+GMA*1 structure Formula (11) SMILES logo COC1=C(O)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 molecular formula C ₂₈ H ₃₀ O ₉ Molecular weight Wmc (g/mol, Dalton) 510

In the contact lens products of the 41st to 44th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 41st to 44th embodiments, please refer to Table 26. Table 26 41st embodiment 42nd embodiment 43rd embodiment 44th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Forty-fifth to forty-eighth embodiments>

In the contact lens products of the 45th embodiment to the 48th embodiment, the curcumin derivatives of the contact lenses have the structure shown in formula (12), and for the details of the curcumin derivatives of the 45th embodiment to the 48th embodiment, please refer to Table 27. Table 27 Curcumin Derivatives Curcumin+GMA*1 structure Formula (12) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)C=C(OCC(O)COC(=O)C(C)=C)\C=C\C2=CC(OC)=C(O)C=C2)=C1 molecular formula C ₂₈ H ₃₀ O ₉ Molecular weight Wmc (g/mol, Dalton) 510

In the contact lens products of the 45th to 48th embodiments, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 45th to 48th embodiments, please refer to Table 28. Table 28 45th embodiment 46th embodiment 47th embodiment 48th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<49th to 52nd embodiment>

In the contact lens products of the 49th embodiment to the 52nd embodiment, the curcumin derivative of the contact lens has a structure shown in formula (13), and for the details of the curcumin derivatives of the 49th embodiment to the 52nd embodiment, please refer to Table 29. Table twenty-nine Curcumin Derivatives Curcumin + GMA*2 structure Formula (13) SMILES logo COC1=C(OCC(O)COC(=O)C(C)=C)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 molecular formula C ₃₅ H ₄₀ O ₁₂ Molecular weight Wmc (g/mol, Dalton) 652

In the contact lens products of the 49th embodiment to the 52nd embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 49th embodiment to the 52nd embodiment, please refer to Table 30. Table Thirty 49th embodiment 50th embodiment 51st embodiment 52nd embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Fifty-third to fifty-sixth examples>

In the contact lens products of the 53rd embodiment to the 56th embodiment, the curcumin derivative of the contact lens has the structure shown in formula (14), and for the details of the curcumin derivatives of the 53rd embodiment to the 56th embodiment, please refer to Table 31. Table 31 Curcumin Derivatives Curcumin + GMA*2 structure Formula (14) SMILES logo COC1=C(O)C=CC(\C=C\C(OCC(O)COC(=O)C(C)=C)=CC(=O)\C=C\C2=CC(OC)=C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 molecular formula C ₃₅ H ₄₀ O ₁₂ Molecular weight Wmc (g/mol, Dalton) 652

In the contact lens products of the 53rd embodiment to the 56th embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 53rd embodiment to the 56th embodiment, please refer to Table 32. Table thirty-two 53rd embodiment 54th embodiment 55th embodiment 56th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Fifty-seventh to sixtieth embodiments>

In the contact lens products of the 57th embodiment to the 60th embodiment, the curcumin derivative of the contact lens has the structure shown in formula (15), and for the details of the curcumin derivatives of the 57th embodiment to the 60th embodiment, please refer to Table 33. Table Thirty-Three Curcumin Derivatives Curcumin + GMA*3 structure Formula (15) SMILES logo COC1=C(OCC(O)COC(=O)C(C)=C)C=CC(\C=C\C(=O)C=C(OCC(O)COC(=O)C(C)=C)\C=C\C2=CC(OC)=C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 molecular formula C ₄₂ H ₅₀ O ₁₅ Molecular weight Wmc (g/mol, Dalton) 794

In the contact lens products of the 57th embodiment to the 60th embodiment, the antioxidant in the buffer solution is vitamin C, and the wetting agent is hyaluronic acid and sodium alginate. For the values of Ccu, Cao, Cad, and Ccu/Cao in the 57th embodiment to the 60th embodiment, please refer to Table 34. Table thirty-four 57th embodiment 58th embodiment 59th embodiment The 60th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 CAD (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

Although the present invention has been disclosed above in terms of implementation, it is not intended to limit the present invention. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be defined by the scope of the appended patent application.

100:Contact lens products 110: contact lenses 120: buffer solution

In order to make the above and other objects, features, advantages and embodiments of the present invention more obvious and understandable, the accompanying drawings are described as follows: Figure 1 is a schematic diagram illustrating a contact lens product according to an embodiment of the present invention; Figure 2 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 280 nm to 310 nm; Figure 3 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 310 nm to 380 nm; Figure 4 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 410 nm to 460 nm; Figure 5 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 460 nm to 780 nm; Figure 6 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 380 nm to 780 nm; Figure 7 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 280 nm to 310 nm; Figure 8 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 310 nm to 380 nm; Figure 9 is a diagram showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 410 nm to 460 nm; Figure 10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 460 nm to 780 nm; and Fig. 11 is a diagram showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 380 nm to 780 nm.

100:Contact lens products

110: contact lenses

120: buffer solution

Claims (17)

A contact lens product comprising: a contact lens; and a buffer solution, the contact lens is preserved in the buffer solution, wherein the buffer solution comprises at least one antioxidant; wherein the contact lens comprises at least one curcumin derivative, and the curcumin derivative has a structure as shown in formula (I) or formula (II): Formula (I), wherein at least one _of R and _R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylic acid-2,3-dihydroxypropyl and hydrogen, and _R and _R are not simultaneously hydrogen; or Formula (II), Wherein at least _{one of} R and _R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylic acid-2,3-dihydroxypropyl and hydrogen, R is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl, and R and _R are not hydrogen at the same time _. The contact lens product as claimed in claim 1, wherein at least one of R1 and _R2 of the formula ( _I ) is hydroxyethyl methacrylate, or at least one of _R3 and _R4 of the formula (II) is hydroxyethyl methacrylate. The contact lens product as described in Claim 1, wherein R ₅ of the formula (II) is methacrylic acid or 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester. The contact lens product as described in claim item 1, wherein the concentration by weight of the curcumin derivative in the contact lens is Ccu, and the concentration by weight of the antioxidant in the buffer solution is Cao, which meets the following conditions: 0.02 ≤ Ccu/Cao ≤ 10.00. The contact lens product as described in claim item 4, wherein the concentration by weight of the curcumin derivative in the contact lens is Ccu, which meets the following conditions: 0.02% ≤ Ccu ≤ 5.00%. The contact lens product as described in claim item 5, wherein the weight percent concentration of the antioxidant in the buffer solution is Cao, which meets the following conditions: 0.06% ≤ Cao ≤ 5.00%. The contact lens product as described in Claim 1, wherein the buffer solution further comprises at least one wetting agent, and the weight percent concentration of the wetting agent is Cad, which satisfies the following conditions: 0.01% ≤ Cad ≤ 1.00%. Contact lens product as described in claim item 1, wherein the molecular weight of this curcumin derivative is Wmc, and it satisfies the following conditions: 410 ≤ Wmc ≤ 800. The contact lens product as described in Claim 1, wherein at least one day after the contact lens is sterilized, the average transmittance of the contact lens at a wavelength of 280 nm to 310 nm is T2831, which meets the following conditions: 50% ≤ T2831 ≤ 90%. The contact lens product as described in Claim 9, wherein at least one day after the contact lens is sterilized, the average transmittance of the contact lens at a wavelength of 310 nm to 380 nm is T3138, which meets the following conditions: 60% ≤ T3138 ≤ 92%. The contact lens product as described in Claim 10, wherein at least one day after the contact lens is sterilized, the average transmittance of the contact lens at a wavelength of 410 nm to 460 nm is T4146, which meets the following conditions: 70% ≤ T4146 ≤ 90%. The contact lens product as described in Claim 1, wherein at least one day after the contact lens is sterilized, the absorption and barrier efficiency of the contact lens at a wavelength of 280 nm to 310 nm is BE2831, which meets the following conditions: 4.0% ≤ BE2831 ≤ 50.0%. The contact lens product as described in Claim 12, wherein at least one day after the contact lens is sterilized, the absorption and barrier efficiency of the contact lens at a wavelength of 310 nm to 380 nm is BE3138, which meets the following conditions: 3.0% ≤ BE3138 ≤ 35.0%. The contact lens product as described in Claim 13, wherein at least one day after the contact lens is sterilized, the absorption and barrier efficiency of the contact lens at a wavelength of 410 nm to 460 nm is BE4146, which meets the following conditions: 1.0% ≤ BE4146 ≤ 30.0%. The contact lens product according to claim 1, wherein the contact lens further comprises at least one myopia control agent. The contact lens product according to claim 1, wherein the contact lens further comprises at least one benefit agent. The contact lens product as claimed in claim 1, wherein a package of the contact lens product comprises biodegradable plastic.

Images